The Pandemic Forces the Smart Approach to XOM Stock

The Pandemic Forces the Smart Approach to XOM Stock

For most companies, the coronavirus from China represents a nasty black swan event. Few organizations, though, are as negatively impacted as Exxon Mobil (NYSE:XOM). Obviously, as a traditional energy giant, XOM stock is tied to oil demand. And that has simply fallen off a cliff, with no great indicators that it will rebound anytime soon.Source: Michael Gordon / Shutterstock.com As you might expect, member states of the Organization of the Petroleum Exporting Countries (OPEC) are scrambling for emergency measures. This is about as hard of a hard stop as you can get. Once health authorities failed to contain the coronavirus within China's borders, it was inevitable that it would cross international communities.Even more bad news for XOM stock, whatever OPEC does may be too little, too late. In a CNN Business report, research firm IHS Markit anguished that "oil demand will suffer its steepest decline on record in the first quarter...

Virus Makes Lobsters So Cheap That Sellers Face a Fatal Blow

(Bloomberg) -- The coronavirus outbreak is turning one luxury treat reserved for special occasions into a meal bargain hunters can afford.U.S. lobster prices have plummeted to the lowest in at least four years after the spread of the virus halted charter flights to Asia at a time when sales usually boom for Chinese New Year celebrations.The fallout has left thousands of pounds of unsold lobster flooding North American markets and squeezing U.S. businesses that were already hurting from lost sales due to China’s tariffs from its trade war with Washington.“This is like a fatal blow,” said Stephanie Nadeau, owner of Arundel, Maine-based The Lobster Co., which saw orders to Hong Kong shrivel from about 1,000 boxes a week to a total of 120 boxes -- each carrying 33 pounds -- since late January. “I’m about to lay off most of my employees.”The U.S. used to be the main supplier of live...

Amarin Stock Looks Like a Heart-Healthy Buy on the Dip

The weak performance of Amarin (NASDAQ:AMRN) has been a head scratcher. Back in December, the company announced a major approval from the U.S. Food and Drug Administration. There was also a strong fourth-quarter report.Source: Pavel Kapysh / Shutterstock.com But Wall Street didn't really care. Since early December, Amarin stock has gone from $24 to $16.Now the recent volatility in the markets has taken a toll, no doubt. And there are some other worries about the company's aggressive spending to build out its infrastructure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsYet despite all this, I think the selloff in Amarin stock has been an overreaction. Why? Well, let's take a deeper look at some of recent developments.First of all, the FDA approval was definitely a game changer. The agency agreed to a new indication and label expansion for the flagship drug, Vascepa. Note that the drug was shown to reduce...

Even If Its Outlook Improves, FSLR Stock Is Not the Best Solar Name

First Solar (NASDAQ:FSLR) is not a bad stock to buy, since its solar module business is growing meaningfully and its valuation is low. But with the company in a state of flux and failing to provide either great value or rapid growth, there are much better solar stocks to buy at this point. Further, FSLR stock could be meaningfully hurt both by likely reductions of U.S. tariffs on imports of solar energy products from China and scheduled cuts in the U.S. solar tax credit.Source: IgorGolovniov / Shutterstock.com In conjunction with its fourth-quarter results, the company on Feb. 20 announced that it would "review options for its U.S. project development business." Translated into normal English, that means First Solar will likely look to sell its business that develops large-scale, solar power projects in the U.S.On this issue, I agree with the sentiments expressed by two analysts. Oppenheimer analyst Colin Rusch says that...